<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Shear-induced aggregation requires the platelet <z:chebi fb="2" ids="17089">glycoprotein</z:chebi> complexes (Gp), the <z:e sem="disease" ids="C0042974" disease_type="Disease or Syndrome" abbrv="">von Willebrand</z:e> factor (vWf) and <z:chebi fb="13" ids="16761">ADP</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>The <z:e sem="disease" ids="C0005129" disease_type="Disease or Syndrome" abbrv="">Bernard Soulier syndrome</z:e> (BS) and the <z:e sem="disease" ids="C0272302" disease_type="Disease or Syndrome" abbrv="GPS">gray platelet syndrome</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GPS</z:e>) are platelet function defects characterized by absence of GP Ib/IX and alpha granules, respectively, with mucocutaneous <z:mp ids='MP_0001914'>hemorrhages</z:mp>, <z:hpo ids='HP_0003010'>prolonged bleeding time</z:hpo> (BT) and moderate <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> in both syndromes </plain></SENT>
<SENT sid="2" pm="."><plain>There are reports that desmopressin (DDAVP) shortens the BT in some patients with platelet dysfunction </plain></SENT>
<SENT sid="3" pm="."><plain>The purpose of this study was to evaluate the response t(DDAVP) in four female patients (2 with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GPS</z:e> plus <z:e sem="disease" ids="C0024796" disease_type="Disease or Syndrome" abbrv="MFS|MFS1">Marfan's disease</z:e> and 2 BS) </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> had <z:mp ids='MP_0001914'>bleeding</z:mp> episodes, BTs &gt; 10 minutes, platelet counts (PC) between 40-88 x 10(9)/L and defects in platelet aggregation </plain></SENT>
<SENT sid="5" pm="."><plain>The DDAVP was administered at a dose of 0.3 microgram/kg in 15 to 30 mL of isotonic saline given by slow intravenous drip in 30 to 45 min </plain></SENT>
<SENT sid="6" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients were studied before and after DDAVP administration (BT, PC, platelet factor, mean platelet volume, factors F.VIII:C, FvW:Ag, FvW:RiC of, and platelet aggregation) </plain></SENT>
<SENT sid="7" pm="."><plain>After DDAVP infusion the patients had a BT &lt; 6 min, and increased levels of F </plain></SENT>
<SENT sid="8" pm="."><plain>VIII:C, FvW:Ag and FvW:RiC of (&gt; 100 Ul/dL), and the <z:mp ids='MP_0001914'>bleeding</z:mp> disappeared </plain></SENT>
<SENT sid="9" pm="."><plain>We conclude that there was a good response to DDAVP probably associated with improved platelet <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e>, and increases in the multimers of the <z:e sem="disease" ids="C0042974" disease_type="Disease or Syndrome" abbrv="">von Willebrand</z:e> factor </plain></SENT>
</text></document>